DNA methylation

BioVie Presents Data Showing Potential for Bezisterim (NE3107) to Reduce Inflammation and Restore Homeostasis in a Manner Correlated with Alzheimer’s Disease and Biomarker Endpoints

Retrieved on: 
星期四, 四月 25, 2024
Political moderate, Inflammation, International, M1, WHO, Notifiable disease, USAN, Liver disease, Homeostasis, Chronic obstructive pulmonary disease, World Health Organization, Randomness, Monocyte, CVD, Drug development, Sepsis, DNA methylation, Microglia, Doctor of Philosophy, Dementia, Respiratory disease, Disease, IBD, INN, DNA, CKD, Exercise, Data, Inflammatory bowel disease, Diet, Patient, Macrophage, Metabolism, Cardiovascular disease, Jools' Annual Hootenanny, PD, Cancer, Chronic kidney disease, Gene, COPD, Vaccine

The DNA methylation dataset assessed the extent of DNA methylation on roughly 965,000 individual sites where methyl groups can be attached to the patients’ DNA.

Key Points: 
  • The DNA methylation dataset assessed the extent of DNA methylation on roughly 965,000 individual sites where methyl groups can be attached to the patients’ DNA.
  • But these data provide evidence that bezisterim may have the potential to help keep people healthier for a longer time as we age,” said Cuong Do, BioVie’s President and CEO.
  • “BioVie believes that DNA methylation may not need to constantly increase as we age, and thus the progression of age-related disease may not be uni-directional.
  • This suggests that bezisterim disrupted the negative consequences of DNA methylation that promotes inflammation and restored homeostasis.

BioVie to Present Data Showing How NE3107 Potentially Restores Homeostasis via Specific Genes Associated with Dementia, Metabolism, and Inflammation

Retrieved on: 
星期四, 四月 18, 2024
International, WHO, EDT, USAN, World Health Organization, Randomness, Drug development, Poster, DNA methylation, INN, DNA, Vaccine

Additionally, the United States Adopted Names (USAN) Council, and the World Health Organization (WHO) International Nonproprietary Names (INN) expert committee has approved “bezisterim” as the non-proprietary (generic) name for NE3107, an orally active partial NF-κB inhibitor product candidate being studied in Parkinson’s Disease and Alzheimer’s Disease.

Key Points: 
  • Additionally, the United States Adopted Names (USAN) Council, and the World Health Organization (WHO) International Nonproprietary Names (INN) expert committee has approved “bezisterim” as the non-proprietary (generic) name for NE3107, an orally active partial NF-κB inhibitor product candidate being studied in Parkinson’s Disease and Alzheimer’s Disease.
  • The oral presentation titled “Clinical Outcomes and Biomarker Findings from a Randomized, Placebo-Controlled Trial of NE3107 in Subjects with Mild to Moderate Probably Alzheimer’s Disease” will be presented by Christopher L. Reading, BioVie’s Senior Vice President, Alzheimer’s Disease Program, on Wednesday, April 24 at 2:30 p.m. EDT.
  • The poster with the same title will be presented at 6:45 p.m. on the same day.
  • Details of the presented data and conclusions will be announced once the presentations are made public at the conference.

New Precision Oncology Tests to Drive Personalised Therapies and Improved Treatment Outcomes

Retrieved on: 
星期三, 四月 17, 2024
USD, Brain, University, Cancer, Genomics, Mutation, GTG, Methylation, Health, Survival, Breast, DNA methylation, ASX, DNA, Patient, GVR, Lung, Disease, Melanoma, Neoplasm, Liquid biopsy, Medical imaging

Huge market opportunity for this advanced portfolio of methylation, mutation and liquid biopsy tests.

Key Points: 
  • Huge market opportunity for this advanced portfolio of methylation, mutation and liquid biopsy tests.
  • Earlier detection of a range of cancers leads to significantly improved patient outcomes.
  • This will significantly drive uptake by making genomic tests widely available and financially accessible to eligible patients.
  • This portfolio of new genomic tests will dramatically change the landscape of oncology diagnostics and help achieve better treatment outcomes for patients.

Cardio Diagnostics Announces Publication of Study Showing That its PrecisionCHD™ Test Could Save Health Insurers Over $113 Million Annually

Retrieved on: 
星期一, 四月 29, 2024
Technology, Insurance, Health Technology, Professional Services, Cardiology, Health Insurance, Software, General Health, Health, Artificial Intelligence, Use, Radiation, University, Part, Telehealth, Diagnosis, AUC, Hospital, SPECT, Care, Cardiovascular disease, Prevalence, Molina Healthcare, Methylation, American Medical Association, Death, DNA methylation, MD, Doctor of Philosophy, CHD, Advances in Therapy, DNA, Algorithm, Patient, Moyamoya disease, CPT, PLA, Medicare, Biomarker, Intermountain Health, Associate, Medicine, VBC, Economics, CCTA, Journal, American Heart Association

PrecisionCHD is an AI-powered multiomic DNA test using epigenetic and genetic biomarkers to aid in the detection of stable CHD.

Key Points: 
  • PrecisionCHD is an AI-powered multiomic DNA test using epigenetic and genetic biomarkers to aid in the detection of stable CHD.
  • The model considered factors such as the number of tests performed, the cost of each test, and the impact of test results on treatment decisions.
  • The results suggest that using PrecisionCHD could lead to significant cost savings for payers, with an estimated $113.6 million saved per year for a plan with one million members.
  • These tools support targeted, data-driven decisions in CHD treatment and management, potentially revolutionizing approaches to healthcare delivery and cost management.

Epigenetic Laboratories Partner to Increase Access to Early Cancer Detection Technology, as U.S. Braces for Record High New Cancer Cases

Retrieved on: 
星期五, 四月 12, 2024
FDA, University, Cancer, MCD, Epigenome, Breast, DNA methylation, Partnership, Research, DNA, Science, Epigenomics, Medicine, Patient, Physician, Diagnosis, EST, Government, Liquid biopsy

Laying the groundwork for revolutionary solutions to these screening pitfalls, epigenetic laboratories Precision Epigenomics and TruDiagnostic announce a new, U.S. based partnership.

Key Points: 
  • Laying the groundwork for revolutionary solutions to these screening pitfalls, epigenetic laboratories Precision Epigenomics and TruDiagnostic announce a new, U.S. based partnership.
  • With a network of 40,000 integrative medicine clinicians across the country, TruDiagnostic is able to extend access to Precision Epigenomics' novel, blood-based, multiscreening cancer test EPISEEK™.
  • TruDiagnostic was built to serve healthcare providers, and EPISEEK testing through their laboratory would be conducted only under a prescription order.
  • That's why Bernert's team focused their research on Multi-Cancer Detection blood tests (liquid biopsies) that evaluated epigenetic markers of cancer.

Nucleix Demonstrates Potential of its PCR EpiCheck® Assay to Accurately Differentiate Between Small Cell Lung Cancer (SCLC) Subtypes

Retrieved on: 
星期四, 四月 4, 2024
Research, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Science, Oncology, Diagnosis, PCR, Plasma, Carcinoma, Cancer cell, Protocol, Biomarker, DNA, Classification, University, MD Anderson Cancer Center, DNA methylation, AACR, Liquid biopsy, SCLC, Medical imaging

Nucleix , a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, today announced data from a pilot study demonstrating the potential of a simple PCR assay based on EpiCheck® technology to accurately differentiate between small cell lung cancer (SCLC) subtypes.

Key Points: 
  • Nucleix , a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, today announced data from a pilot study demonstrating the potential of a simple PCR assay based on EpiCheck® technology to accurately differentiate between small cell lung cancer (SCLC) subtypes.
  • The Company is presenting the data in a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego, April 5-10.
  • The 13-marker PCR assay developed for this pilot study stemmed from data from a recent study published in Cancer Cell demonstrating the detection of SCLC using DNA methylation in plasma samples from heavy smokers, yielding a sensitivity of 94% and specificity of 95%.
  • In the data being presented at AACR, the 13-marker PCR assay correctly classified 97% of the SCLC tissue samples in a blinded cohort.

DNA Methylation Detection Technology Market Research 2024 - Global Forecast to 2033 Featuring Prominent Players - Thermo Fisher Scientific, Illumina, QIAGEN, Zymo Research, and Agilent Technologies - ResearchAndMarkets.com

Retrieved on: 
星期二, 四月 2, 2024
Biotechnology, Genetics, Health, Diagnosis, PCR, Growth, Drug discovery, Thermo Fisher Scientific, Biomarker, Research, DNA, Competitive landscape, Real-time, Microarray, Cancer, Software, DNA methylation, Agilent Technologies, DSM-IV codes, QIAGEN, MSP, Prognosis, Marketing, Medicine, Fine chemical

The global DNA methylation detection technology market is projected to experience substantial growth over the forecast period 2023-2033.

Key Points: 
  • The global DNA methylation detection technology market is projected to experience substantial growth over the forecast period 2023-2033.
  • In the DNA methylation detection technology market, several key players dominate the landscape with their diverse range of products and solutions.
  • Thermo Fisher Scientific, Illumina, Inc. QIAGEN, Zymo Research Corporation, and Agilent Technologies, Inc. are among the prominent market players offering innovative tools and platforms for DNA methylation analysis.
  • The global DNA methylation detection technology market can be considered to be in the mature growth stage of its lifecycle.

EpiMedTech Global to Present Revolutionary Epigenetics Research at MedInvest Biotech & Pharma Investor Conference

Retrieved on: 
星期二, 四月 2, 2024
Conference, Gene expression, Syndrome, FRSC, DNA, Cancer, DNA methylation, Embryo, FCAHS, HKG, Ageing, Vaccine

The presentation will spotlight groundbreaking advancements in DNA methylation and its significant potential in transforming global healthcare through early disease detection.

Key Points: 
  • The presentation will spotlight groundbreaking advancements in DNA methylation and its significant potential in transforming global healthcare through early disease detection.
  • DNA methylation, a critical process in epigenetic signaling, acts as a sophisticated regulatory mechanism, controlling gene expression without altering the DNA sequence itself.
  • "EpiMedTech Global is at the forefront of leveraging DNA methylation for early disease detection, aiming to bridge the vast gap between the potential of epigenetic research and its current clinical application," said Prof. Szyf.
  • Join us at MedInvest to discover how EpiMedTech Global is paving the way for a future where early detection and prevention are within reach for everyone, everywhere.

DNA Methylation Detection Technology Markets, 2033 - Intensified Competition, Increasing Adoption, PCR Dominates

Retrieved on: 
星期六, 三月 30, 2024
Diagnosis, PCR, Health, Growth, Biotechnology, Drug discovery, Thermo Fisher Scientific, Biomarker, Research, DNA, Competitive landscape, Real-time, Microarray, Cancer, Software, DNA methylation, Agilent Technologies, DSM-IV codes, QIAGEN, MSP, Prognosis, Marketing, Medicine, Fine chemical

In the DNA methylation detection technology market, several key players dominate the landscape with their diverse range of products and solutions.

Key Points: 
  • In the DNA methylation detection technology market, several key players dominate the landscape with their diverse range of products and solutions.
  • Based on technology, the PCR segment accounted for the largest share of the global DNA methylation detection technology market in FY2022.
  • Moreover, PCR is expected to maintain its dominance in the global DNA methylation detection technology market by technology due to its widespread adoption, versatility, and reliability.
  • Based on application, diagnostic research accounted for the largest share of the global DNA methylation detection technology market in FY2022, primarily due to clinicians' increasing focus on utilizing DNA methylation analysis for clinical diagnostics.

BioVie’s NE3107 Demonstrates Potential Improvements in Motor and Non-motor Symptoms for Parkinson’s Disease Patients and May Be Realigning Physiological Processes for Alzheimer’s Patients in Data to be Presented at the International Conference on Alzheime

Retrieved on: 
星期五, 三月 1, 2024
L-DOPA, MCP1, Chemokine, Alzheimer's disease, Phagocytosis, Political moderate, Principal, MDS-UPDRS, Cholesterol, Insulin, Inflammation, Part, ADAS, Plaque, Conference, Placebo-controlled study, Parkinson's disease, Diabetes, Carbidopa/levodopa, Pharmacokinetics, Digestion, Disease, DNA methylation, DNA, Brain, Pharmaceutical industry

CARSON CITY, Nev., March 01, 2024 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced two upcoming presentations at the International Conference on Alzheimer’s and Parkinson’s Diseases 2024 (AD/PD™ 2024) to be held March 5-9, 2024 in Lisbon, Portugal.

Key Points: 
  • These findings complement previously reported improvement in motor symptoms in patients treated with NE3107 and demonstrate potential intrinsic, levodopa-enhancing activity of NE3107 that is consistent with data from animal models.
  • NE3107-treated patients experienced a significant improvement of -2.4 points for the sleep/fatigue domain of the Non-Motor Symptom Scale (NMSS) in Parkinson’s Disease, whereas placebo patients experienced a worsening of +1.0 points (p=0.0159).
  • Sleep/fatigue domain improvements correlated with motor score improvements (r=0.51; p=0.0259).
  • More patients on NE3107 had improvements in the NMSS sleep/fatigue domain, while more patients on placebo worsened.